Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12...102103104105106107108109110111112...136137»
  • ||||||||||  [VIRTUAL] Historical Perspective of Lambert Eaton and Rooke, Myasthenic Syndrome () -  Sep 30, 2020 - Abstract #ANA2020ANA_513;    
    They also described techniques of electromyography, its use and effectiveness in the diagnosis and study of diseases of the motor unit (neuromuscular diseases). We aim to emphasize the historical perspectives that led to the discovery of this unique myasthenic syndrome.
  • ||||||||||  prednisolone / Generic mfg.
    Review, Journal:  Reappraisal of Oral Steroid Therapy for Myasthenia Gravis. (Pubmed Central) -  Sep 30, 2020   
    In 2014, the Japanese clinical guidelines for MG proposed that the first goal in MG treatment (treatment target) should be set at minimal manifestations (MM) with oral prednisolone (PSL) 5 mg/day or below, and that treatment strategies should strive to attain this level as rapidly as possible...These results suggest the limitation of the current oral corticosteroid therapy. We need to develop new treatment options to increase the rate of satisfactory outcome.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Review, Journal, IO Biomarker:  From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for Research. (Pubmed Central) -  Sep 30, 2020   
    Killing of B cells with Rituximab has been proposed and tested with positive results, particularly in patients with MuSK-associated MG...A differently targeted approach involved Eculizumab, a monoclonal antibody preventing the formation of C59b-induced MAC causing destruction of the neuromuscular junction...An even more recent approach is the interference with the neonatal Fc receptor leading to a rapid reduction of circulating IgGs and hence of specific autoantibodies, an approach suitable for both anti-acetylcholine- and MuSK-associated MG. The investigation of compounds that selectively target the immune system will stimulate the search for specific biomarkers of disease activity and response to treatment, setting the basis for personalized medicine in MG.
  • ||||||||||  Clinical, Journal, Checkpoint inhibition:  Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series. (Pubmed Central) -  Sep 30, 2020   
    The evaluation of patients with cardiac adverse events from immunotherapy, should include assessment of overlapping toxicities such as myasthenia gravis and myositis. Providers should be aware of the potential for an extended duration of disability and slow improvement for certain toxicities as these expectations may factor prominently in goals of care decisions.
  • ||||||||||  [VIRTUAL] Frequent Adverse Events with Current Apheresis Port () -  Sep 27, 2020 - Abstract #AABB2020AABB_427;    
    Most serious AE were DVT and SVC-S, which require prompt diagnosis and treatment. Interventional radiology specialists emphasize that appropriate location, depth and procedure technique are critical for successful PF placement and performance.
  • ||||||||||  ritonavir / Generic mfg.
    Clinical, Journal:  Description of 3 patients with myasthenia gravis and COVID-19. (Pubmed Central) -  Sep 27, 2020   
    No abstract available Outcome was favorable in all cases despite immunosuppressive therapy, use of experimental COVID-19 medication and switching of plasma exchange for IVIG.
  • ||||||||||  cyclophosphamide intravenous / Generic mfg., Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Clinical, Journal:  Management Issues in Myasthenia Gravis Patients Living With HIV: A Case Series and Literature Review. (Pubmed Central) -  Sep 27, 2020   
    Eleven developed MG while HIV-infected (mean CD4 423 cells/mm); five presented with mild MG; three in MG crisis requiring rescue therapies (intravenous immune globulin or plasma exchange and/or intravenous cyclophosphamide)...Fifteen required maintenance steroid-sparing immune therapies, predominantly azathioprine, or methotrexate...Conclusions include the following: MG in HIV-infected patients should be managed similarly to individuals without HIV infection; half develop moderate-severe MG; MG symptoms may worsen within 6 months of antiretroviral initiation; safety monitoring must include plasma HIV viral load estimation. Isoniazid prophylaxis may not be indicated in all cases.
  • ||||||||||  Bridion (sugammadex) / Merck (MSD)
    Clinical, Review, Journal:  Use of sugammadex in patients with neuromuscular disorders: a systematic review of case reports. (Pubmed Central) -  Sep 26, 2020   
    However, with sugammadex, unpredictability in response and uncertainty regarding optimum dose still remain issues. Quantitative neuromuscular monitoring to ensure complete reversal and adequate postoperative monitoring is strongly recommended in these patients, despite the use of sugammadex.
  • ||||||||||  tacrolimus / Generic mfg.
    Clinical, Journal:  Clinical effect of tacrolimus in the treatment of myasthenia gravis in children (Pubmed Central) -  Sep 24, 2020   
    Tacrolimus appears to be effective and safe in the treatment of children with MG and is thus an option for immunosuppressive therapy. CYP3A5 genotyping has a certain guiding significance for determining the dosage of tacrolimus.
  • ||||||||||  Journal:  Structure of the Native Muscle-type Nicotinic Receptor and Inhibition by Snake Venom Toxins. (Pubmed Central) -  Sep 23, 2020   
    It also reveals a closed gate in the ion-conducting pore, formed by hydrophobic amino acid side chains, located ∼60 Å from the toxin binding sites. The structure provides a framework for understanding gating in ligand-gated channels and how mutations in the acetylcholine receptor cause congenital myasthenic syndromes.
  • ||||||||||  Biomarker, Journal:  Genetic characterization of thymoma. (Pubmed Central) -  Sep 21, 2020   
    It shed light on the molecular bases for analyzing the functional process of thymoma and finding potential biomarkers for pathological categorizing and treatment. Our work may provide important clues in understanding possible causes of MG in thymoma patients.
  • ||||||||||  Review, Journal:  Application of Plasma Exchange in Steroid-Responsive Encephalopathy. (Pubmed Central) -  Sep 21, 2020   
    Additionally, plasma exchange can also be used alone or in combination with steroids, immunoglobulins, or other immunosuppressive agents to treat steroid-responsive encephalopathy. This paper reviews the clinical application of plasma exchange in steroid-responsive encephalopathy, including its indications, onset time, course, curative effects, and side effects.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma, Ultomiris IV (ravulizumab IV) / Alexion Pharma
    Review, Journal:  Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics. (Pubmed Central) -  Sep 21, 2020   
    Several challenges still exist or will soon present themselves, including mitigation of infection risk, effective monitoring strategies, and how to choose between therapeutics when more than one is available. In this review, we will describe the lessons learned from the "eculizumab era," present many of the novel therapeutics currently or soon to be in trials, and highlight some of the challenges that will require attention as the field progresses.
  • ||||||||||  Journal:  Is chest tube drainage necessary after subxiphoid thoracoscopic thymectomy? (Pubmed Central) -  Sep 20, 2020   
    In this review, we will describe the lessons learned from the "eculizumab era," present many of the novel therapeutics currently or soon to be in trials, and highlight some of the challenges that will require attention as the field progresses. The omission of chest tube drainage may be a feasible and safe choice for patients with myasthenia gravis undergoing subxiphoid thoracoscopic thymectomy, but further prospective studies are required.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    [VIRTUAL] Myasthenia gravis-like myopathy in a case of metastatic cutaneous squamous cell carcinoma under anti-PD-1 therapy. (ePoster Terminal 3) -  Sep 20, 2020 - Abstract #ADO2020ADO_337;    
    Cemiplimab was paused and systemic steroids with prednisolone 0.5 mg/kg PO Q1D were started...Based on the severe adverse reaction Cemiplimab was switched to epidermal growth factor receptor (EGFR) antibody Cetuximab...The patho‐mechanism of anti‐PD‐1 associated myasthenia gravis‐like myopathy as a rare irAE have not been elucidated in detail so far. Further investigations are needed in order to ameliorate the clinical management of this rare irAE.
  • ||||||||||  Remicade (infliximab) / Mitsubishi Tanabe, J&J
    [VIRTUAL] Neurological side effects under immune checkpoint blockade - Interdisciplinary management relevant (Stream 1) -  Sep 20, 2020 - Abstract #ADO2020ADO_226;    
    In our patient with TM, therapy with intravenous immunoglobulins (IVIg) and therapy with infliximab were also carried out...Neurological NW are rare, but can quickly be life-threatening due to a fulminant course. The importance of interdisciplinary / multimodal therapy strategies i.R. tumor therapy and side effect management is increasing in view of the effectiveness of the new drug-based tumor therapies.
  • ||||||||||  Soliris (eculizumab) / Alexion Pharma
    Journal:  Thrombotic microangiopathy in rheumatology: a link between thrombosis and autoimmunity (Pubmed Central) -  Sep 20, 2020   
    Recently, special attention has been paid to the treatment of systemic lupus erythematosus and antiphospholipid syndrome with eculizumab, which is humanized monoclonal IgG2/4k antibody that blocks the complement component C5a and the membrane attack complex (C5b-9) formation, and which is registered for the treatment of atypical hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, as well as severe forms of myasthenia gravis and neuromyelitis optica. Further studies in this direction will create prerequisites for improving the prognosis not only in patients with orphan disorders, but also for widespread human diseases.
  • ||||||||||  Journal:  Conotation of ancient "stroke" and Qianyin Yaofang Xiaoxuming Decoction treating cerebral infarction and cerebral hemorrhage (Pubmed Central) -  Sep 20, 2020   
    According to studies, in the treatment of cerebral infarction and cerebral hemorrhage, Xiaoxuming Decoction can significantly shorten the course of acute stage and promote the recovery of hemiplegia, and its mechanism is consistent with the treatment principle of modern medicine for cerebrovascular diseases. In addition, this prescription is forbidden for patients with red face, fast heart rate, high blood pressure, blocked stool, red tongue, yellow fur, rapid pulse string or strong pulse string, and strong pulse on the wrist.
  • ||||||||||  Journal:  Reply from the authors: Myasthenic crises in COVID-19. (Pubmed Central) -  Sep 20, 2020   
    In addition, this formula is forbidden for those with red face, fast heart rate, high blood pressure, blocked stool, red tongue, yellow fur, wiry and rapid pulse or powerful pulse, and spout pulse. No abstract available
  • ||||||||||  cyclophosphamide intravenous / Generic mfg., Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Journal:  Transverse myelitis syndrom as a result of neuromyelitis optica spectrum disorders, systemic lupus erythematosus and myasthenia gravis combination (Pubmed Central) -  Sep 20, 2020   
    In patients with MG, when symptoms of damage to the central nervous system appear, an analysis should be performed for AQP4-IgG and possibly for antibodies to myelin glycoprotein of oligodendrocytes (MOG-Ab), as well as markers characteristic of systemic connective tissue diseases (SCTD). In patients with STDD, when symptoms of involvement nervous systemappear, testing for AQP4-IgG (and, if necessary, for MOG-Ab) should be performed to exclude NMOSD, as well as AChR-Ab (and, if necessary, antibodies against muscle specific kinase (MuSK-Ab)) to exclude MG.